Literature DB >> 20129934

Rapid eye movement sleep behaviour disorder in patients with narcolepsy is associated with hypocretin-1 deficiency.

Stine Knudsen1, Steen Gammeltoft, Poul J Jennum.   

Abstract

Rapid eye movement sleep behaviour disorder is characterized by dream-enacting behaviour and impaired motor inhibition during rapid eye movement sleep. Rapid eye movement sleep behaviour disorder is commonly associated with neurodegenerative disorders, but also reported in narcolepsy with cataplexy. Most narcolepsy with cataplexy patients lack the sleep-wake, and rapid eye movement sleep, motor-regulating hypocretin neurons in the lateral hypothalamus. In contrast, rapid eye movement sleep behaviour disorder and hypocretin deficiency are rare in narcolepsy without cataplexy. We hypothesized that rapid eye movement sleep behaviour disorder coexists with cataplexy in narcolepsy due to hypocretin deficiency. In our study, rapid eye movement sleep behaviour disorder was diagnosed by the International Classification of Sleep Disorders (2nd edition) criteria in 63 narcolepsy patients with or without cataplexy. Main outcome measures were: rapid eye movement sleep behaviour disorder symptoms; short and long muscle activations per hour rapid eye movement and non-rapid eye movement sleep; and periodic and non-periodic limb movements per hour rapid eye movement and non-rapid eye movement sleep. Outcome variables were analysed in relation to cataplexy and hypocretin deficiency with uni- and multivariate logistic/linear regression models, controlling for possible rapid eye movement sleep behaviour disorder biasing factors (age, gender, disease duration, previous anti-cataplexy medication). Only hypocretin deficiency independently predicted rapid eye movement sleep behaviour disorder symptoms (relative risk = 3.69, P = 0.03), long muscle activations per hour rapid eye movement sleep (ln-coefficient = 0.81, P < 0.01), and short muscle activations per hour rapid eye movement sleep (ln-coefficient = 1.01, P < 0.01). Likewise, periodic limb movements per hour rapid eye movement and non-rapid eye movement sleep were only associated with hypocretin deficiency (P < 0.01). A significant association between hypocretin deficiency and cataplexy was confirmed (P < 0.01). In a sub-analysis, hypocretin deficiency suggested the association of periodic limb movements and rapid eye movement sleep behaviour disorder outcomes (symptoms, non-periodic short and long muscle activity) in rapid eye movement sleep. Our results support the hypothesis that hypocretin deficiency is independently associated with rapid eye movement sleep behaviour disorder in narcolepsy. Thus, hypocretin deficiency is linked to the two major disturbances of rapid eye movement sleep motor regulation in narcolepsy: rapid eye movement sleep behaviour disorder and cataplexy. Hypocretin deficiency is also significantly associated with periodic limb movements in rapid eye movement and non-rapid eye movement sleep, and provides a possible pathophysiological link between rapid eye movement sleep behaviour disorder and periodic limb movements in narcolepsy. The study supports the hypothesis that an impaired hypocretin system causes a general instability of motor regulation during wakefulness, rapid eye movement and non-rapid eye movement sleep in human narcolepsy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20129934     DOI: 10.1093/brain/awp320

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  36 in total

Review 1.  Diagnostic tools for REM sleep behavior disorder.

Authors:  Ariel B Neikrug; Sonia Ancoli-Israel
Journal:  Sleep Med Rev       Date:  2011-12-14       Impact factor: 11.609

Review 2.  Rapid eye movement sleep behavior disorder and the link to alpha-synucleinopathies.

Authors:  Daniel A Barone; Claire Henchcliffe
Journal:  Clin Neurophysiol       Date:  2018-05-29       Impact factor: 3.708

3.  Loss of rapid eye movement sleep atonia in patients with REM sleep behavioral disorder, narcolepsy, and isolated loss of REM atonia.

Authors:  Aytakin Khalil; Mary-Anne Wright; Matthew C Walker; Sofia H Eriksson
Journal:  J Clin Sleep Med       Date:  2013-10-15       Impact factor: 4.062

4.  Normal Morning Melanin-Concentrating Hormone Levels and No Association with Rapid Eye Movement or Non-Rapid Eye Movement Sleep Parameters in Narcolepsy Type 1 and Type 2.

Authors:  Maren Schrölkamp; Poul J Jennum; Steen Gammeltoft; Anja Holm; Birgitte R Kornum; Stine Knudsen
Journal:  J Clin Sleep Med       Date:  2017-02-15       Impact factor: 4.062

5.  Mortality and Its Risk Factors in Patients with Rapid Eye Movement Sleep Behavior Disorder.

Authors:  Junying Zhou; Jihui Zhang; Siu Ping Lam; Vincent Mok; Anne Chan; Shirley Xin Li; Yaping Liu; Xiangdong Tang; Wing Ho Yung; Yun Kwok Wing
Journal:  Sleep       Date:  2016-08-01       Impact factor: 5.849

6.  Sleep transitions in hypocretin-deficient narcolepsy.

Authors:  Gertrud Laura Sorensen; Stine Knudsen; Poul Jennum
Journal:  Sleep       Date:  2013-08-01       Impact factor: 5.849

7.  The diagnostic value of power spectra analysis of the sleep electroencephalography in narcoleptic patients.

Authors:  Julie Anja Engelhard Christensen; Emil Gammelmark Schreiner Munk; Paul E Peppard; Terry Young; Emmanuel Mignot; Helge Bjarrup Dissing Sorensen; Poul Jennum
Journal:  Sleep Med       Date:  2015-09-15       Impact factor: 3.492

8.  Dream enactment behavior: review for the clinician.

Authors:  Marc Baltzan; Chun Yao; Dorrie Rizzo; Ron Postuma
Journal:  J Clin Sleep Med       Date:  2020-11-15       Impact factor: 4.062

9.  Morbidities in rapid eye movement sleep behavior disorder.

Authors:  Poul Jennum; Geert Mayer; Yo-El Ju; Ron Postuma
Journal:  Sleep Med       Date:  2013-01-29       Impact factor: 3.492

10.  Attenuated heart rate response is associated with hypocretin deficiency in patients with narcolepsy.

Authors:  Gertrud Laura Sorensen; Stine Knudsen; Eva Rosa Petersen; Jacob Kempfner; Steen Gammeltoft; Helge Bjarup Dissing Sorensen; Poul Jennum
Journal:  Sleep       Date:  2013-01-01       Impact factor: 5.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.